不同剂型复方黄根治疗慢性乙型肝炎的临床观察

Clinical Research on Treatment of Chronic Hepatitis B with Compound huanggen of Different Preparations

目的:观察复方黄根颗粒(达肝清颗粒)治疗慢性乙型肝炎的临床疗效。方法:将66例慢性乙型肝炎患者随机分为两组,复方黄根颗粒组和复方黄根汤剂组各33例,两组患者均使用药物组成相同但剂型不同的复方黄根治疗,疗程均为3个月,观察治疗前后症候积分、肝功能、血清HBV-M、HBV-DNA及部分患者HA、LN和Ⅳ-C等三项肝纤维化指标的变化。结果:两组症状均有明显改善(P<0.01),ALT及AST水平均显著降低(P<0.01),血清HBV-DNA含量均明显下降(P<0.01),HA、LN和Ⅳ-C肝纤维化指标均有明显下降(P<0.01),但两组间比较均无显著差异(P>0.05);两组均有部分HBeAg阴转和HBeAg/抗HBe血清转换,但两组间比较无显著性差异(P>0.05)。结论:复方黄根颗粒对慢性乙型肝炎具有较好的改善症状、保肝降酶、抗乙肝病毒、抗肝纤维化的作用,与复方黄根汤剂疗效无差异。

objective： To observe the clinical effect of compound Methods：66 patients with chronic hepatitis B were randomly divided into the compound group with huangge n huanggen granule group and the compound 33 cases for each. Patients in both groups were given compound with the same ingredients but different preparations, and the medication lasted for three months. Symptom points, liver function, serum HBV-M, HBV-DNA and changes of the three indices, including serum hyaluronic acid （HA）, laminin （LN） and collagen type IV （IV-C）, of hepatic fibrosis in some patients, were all observed before and after the treatment. Results：In both groups, symptoms significantly released （P〈0.01 ）, alanine aminotransferase （ALT）, aspartate aminotransferase （AST）, serum HBV-DNA, as well as the three indices of hepatic fibrosis were significantly reduced （P〈0.01）, but without significant difference between these two groups （P〉0.05）. Besides, HBeAg negative conversion/anti-HBe seroconversion happened on some patients in both groups, but without difference between the two （P〉0.05）. Conclusion：Compound huanggen granule and compound huanggen decoction in both groups have the same good effect against chronic hepatitis B, on releasing symptoms, protecting the liver and lowering aminotransferase, anti-hepatitis B virus, and anti-hepatic fibrosis.